ArticleSisli Etfal Hastanesi tip bulteni2025
Effects of Oral Isotretinoin on Skin and Serum Levels of FoxO3, TRAIL and p53 and Metabolic Parameters.
Article in Sisli Etfal Hastanesi tip bulteni, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Isotretinoin-mediated apoptosis is considered the main cause of anti-acne side effects of isotretinoin. The aim of this study is to investigate the effects of oral isotretinoin therapy on the skin and serum levels of forkhead box transcription factor (FoxO)-3, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), p53 and metabolic parameters and examine the relationship between these parameters. Methods: Sixteen acne vulgaris patients who were administered the appropriate cumulative dose of oral isotretinoin were enrolled in this prospective study. Results: The decreases in the values of body mass index, waist circumference, systolic blood pressure (BP), CRP, and ferritin from the baseline to the end of the treatment were statistically significant (p=0.028, p=0.029, p=0.008, p=0.046, and p=0.003, respectively). The increases in the levels of serum low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), total cholesterol, gamma-glutamyl transferase (GGT), and FoxO3 from the baseline to the end of the treatment were statistically significant (p=0.001, p=0.004, p<0.001, p=0.010, p=0.007, respectively). In terms of changes from the baseline to the end of the treatment, serum FoxO3 levels were positively correlated with the changes in serum TRAIL levels (r=0.674, p=0.004). The changes in serum FoxO3 levels were positively correlated with the changes in fasting blood glucose levels (r=0.540, p=0.031). The changes in serum TRAIL levels were positively correlated with the changes in the values of systolic BP (r=0.552, p=0.027) and diastolic BP (r=0.511, p=0.043). The changes in serum p53 levels and serum LDL-C levels were also positively correlated (r=0.499, p=0.049). Conclusion: Isotretinoin therapy caused an increase in skin and serum levels of FoxO3 and TRAIL and a decrease in serum and skin p53 values. However, only the increase in serum FoxO3 levels was statistically significant. The observed reduction in p53 levels implies that the isotretinoin-related side effects may not rely on p53-mediated apoptosis, and it may be considered that its safety profile is better than expected. The correlations between the changes during isotretinoin therapy in metabolic parameters and TRAIL, p53, and FoxO3 values suggest that isotretinoin's metabolic side effects may involve these molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.